FDA approves subcutaneous injectable for myasthenia gravis treatment.
TL;DR
The FDA has approved a new injectable version of argenx's autoimmune disease drug Vyvgart, marketed as Vyvgart Hytrulo, for people with generalized myasthenia gravis. The condition causes a person's immune system to make antibodies that attack their muscles, making movement, speaking, and swallowing difficult and life-threatening when it impedes breathing. The new version will be available in July.
Topics:businesshealthcare#argenx#autoimmune-disease#fda#healthcare#myasthenia-gravis#vyvgart-hytrulo
- FDA approves injectable form of argenx’s myasthenia gravis drug Vyvgart Endpoints News
- Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis Benzinga
- FDA Approves Subcutaneous Efgartigimod as Treatment for Generalized Myasthenia Gravis Neurology Live
- FDA Approves First Subcutaneous Injectable for Muscle-Weakening Disease BioSpace
- argenx Announces U.S. Food and Drug Administration Approval GlobeNewswire
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News